SEC Hits Valeant With Multi-Pronged Probe
Valeant Pharmaceuticals International announced Monday that the U.S. Securities and Exchange Commission was investigating possible share trading irregularities surrounding the release of trial data for the company's hepatitis C drug, Viramidine....To view the full article, register now.
Already a subscriber? Click here to view full article